Windward Bio Group AG WWB

Morningstar Rating
$25.25 −4.44 (14.96%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

WWB is trading at a LOCK|wpkJ%t premium.
Price
$29.85
Fair Value
LOCK|.B#R?&@
Uncertainty
LOCK|y& F<<JT
1-Star Price
LOCK|.s>dr@h<
5-Star Price
LOCK|.WR>rY<
Economic Moat
LOCK|%@C
Capital Allocation
—

News

Trading Information

Previous Close Price
$30.04
Day Range
$22.55–27.51
52-Week Range
$18.47–33.75
Bid/Ask
$24.96 / $25.56
Shares Outstanding
58.04M
Market Cap
$1.43B
Volume/Avg
207,132 / 760,202

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. Its flagship program is WIN378, a potentially novel, long-acting, anti-TSLP monoclonal antibody. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bi-specific, which has therapeutic application across immunological diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
—
Total Number of Employees
—

Valuation

Metric
WWB
Price/Earnings (Normalized)
—
Price/Book Value
—
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
WWB
Quick Ratio
8.49
Current Ratio
8.57
Interest Coverage
−6,842.30
Quick Ratio
WWB

Profitability

Metric
WWB
Return on Assets (Normalized)
−24.26%
Return on Equity (Normalized)
−27.01%
Return on Invested Capital (Normalized)
−27.04%
Return on Assets
WWB

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|TCfpmkLOCK|?Ln<$136B
Regeneron Pharmaceuticals Inc
REGN
LOCK|xnr!g?NLOCK|!#?>$99B
Moderna Inc
MRNA
LOCK|V<ZmghLOCK|xx$87B
argenx SE ADR
ARGX
LOCK|&&&VN#LOCK|CZ!$61B
BeOne Medicines Ltd ADR
ONC
LOCK|S^yTtFLOCK|&k$48B
Royalty Pharma PLC Class A
RPRX
LOCK|h#rPgWvQLOCK|KHv$$31B
Incyte Corp
INCY
LOCK|>FyT%?&LOCK|K&#$25B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|Q!<qnqsLOCK|ZNtt$21B
BioNTech SE ADR
BNTX
LOCK|&>l<f>LLOCK|%?$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|<$W%dkjLOCK|#!$15B

Sponsor Center